Table 5.
Sensitivity, Specificity, PPV, and NPV of mSEPT9, tumor markers and CECT for recurrence
| Sensitivity | Specificity | PPV | NPV | |
|---|---|---|---|---|
| mSEPT9 | 71.4% (47.7%~ 87.8%) |
98.0% (87.8%~ 99.9%) |
93.8% (67.7%~ 99.7%) |
88.9% (76.7%~ 95.4%) |
| CEA | 52.4% (30.3–73.6%) |
91.8% (79.5%~ 97.4%) |
73.3% (44.8%~ 91.1%) |
81.8% (68.6%~ 90.5%) |
| CA19–9 | 33.3% (15.5–56.9%) |
89.9% (77.0–96.2%) |
58.3% (28.6–83.5%) |
75.9% (62.5–85.7%) |
| CA724 | 42.9% (22.6–65.6%) |
93.9% (82.1–98.4%) |
75.0% (42.8–93.3%) |
79.3% (66.3–88.4%) |
| CECT | 85.7% (62.6–96.2%) |
98.0% (87.8%~ 99.9%) |
94.7% (71.9–99.7%) |
94.1% (82.8–98.5%) |